Zanamivir is an antiviral medication belonging to the neuraminidase inhibitor class, widely used to treat influenza A and B infections by inhibiting the enzyme responsible for the release of new viral… Read more














Zanamivir is an antiviral medication belonging to the neuraminidase inhibitor class, widely used to treat influenza A and B infections by inhibiting the enzyme responsible for the release of new viral particles from infected host cells. To ensure strict quality control and regulatory compliance, pharmaceutical laboratories utilize a comprehensive range of Zanamivir reference standards, including pharmacopeial and non-pharmacopeial impurities, potential degradants, and process-related compounds. These materials are essential for accurate impurity profiling and method validation during stability testing and routine batch analysis. Furthermore, stable isotope labelled compounds are available to serve as reliable internal standards in mass spectrometry-based bioanalytical assays, ensuring precision in quantification. By employing these high-quality analytical standards, researchers can effectively identify, monitor, and control potential impurities throughout the development and manufacturing lifecycle of this neuraminidase inhibitor.